logo-nav.png

  • Home

  • Team

  • Science

  • Pipeline

  • News

  • Contact

  • More

    Use tab to navigate through the menu items.
    news-subhead.jpg

    News

    • All Posts
    • Press Releases
    • In the News
    • Jun 15

    Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184

    • Mar 30

    Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome in Alzheimer's Disease

    halia-footer.jpg
    logo-nav.png
    1865 W 2100 S, Suite 100
    Salt Lake City, Utah 84119
    info@haliatherapeutics.com +1 (385) 355-4315
    ©2022 Halia Therapeutics, Inc. All rights reserved.

    ​

    Thanks for subscribing!

    Privacy Policy | Terms of Use
    • LinkedIn